Dr. Michael Har-Noy, CEO and founder of Immunovative Therapies, Ltd., a biotechnology company in Israel, says that the immunotherapy of cancer attempts to restore the ability of the patient’s immune system to seek out and remove malignant cells. Along with chemotherapy, radiation and surgery used in the therapy of cancer. Dr. Michael Har-Noy says that […]
Dr. Michael Har-Noy, founder of the Israeli biotechnology company Immunovative Therapies, Ltd., indicates that HIV infection results in significant loss of the production of interferon. Gamma interferon is a cytokine that is produced primarily from Th1 helper cells. Gamma interferon is crucial for the suppression of viral replication. Dr. Michael Har-Noy says that in cancer […]
Dr. Michael Har-Noy says the initial protocol involves 28 days of treatment. Specifically, the regimen begins with intradermal AlloStimTM on days zero and three, followed by one mL of intravenous AlloStimTM on day seven. Two more intradermal AlloStimTM injections are given on days 10 and 14, followed by three mL of AlloStimTM on day 17. […]
Therapeutic HIV vaccines, says Dr. Michael Har-Noy, CEO of Immunovative Therapies, Ltd., are designed to control HIV infection by improving the body’s natural immunologic response. Currently there are no HIV vaccines that are approved by the FDA. Dr. Michael Har-Noy goes on to say that Natural Killer (NK) cell and that Cytotoxic T lymphocyte (CTL) […]
Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies Ltd., describes the “Mirror EffectTM” as an immune mechanism that solves the problem of separating the curative graft versus tumor (GVT) effect of bone marrow transplant (BMT) procedures from the lethal graft versus host disease (GVHD) complication. Dr. Michael Har-Noy says the solution was to create […]
Concept of Mirror Effect Breakdown of Study Patients Outcome Data For Patients Adverse Effects of AlloStim vs. Drugs on Market
Response of HER2+ breast cancer patients to allogeneic cell immunotherapy. Meeting: 2012 ASCO Annual Meeting Abstract Number: e13013 Citation: J Clin Oncol 30, 2012 (suppl; abstr e13013) Author(s): Michael Har-Noy, Wirote Lausoontornsiri, Reuven Or, Emmanual Katsanis; Immunovative Therapies, Ltd, Jerusalem, Israel; Clinical Cancer Research Department, National Cancer Institute of Thailand, Bangkok, Thailand; Hadassah Hebrew […]
For the official Immunovative Therapies, Ltd. corporate website, please visit www.immunovative.co.il Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with utologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine. Epple LM, Bemis LT, Cavanaugh RP, Skope A, Mayer-Sonnenfeld T, Frank C, Olver CS, Lencioni AM, Dusto NL, Tal A, Michael Har-Noy,* Lillehei KO, Katsanis E, […]